BMD003 (CFTR mRNA)

Phase 1RNA therapy

PPeking Union Medical College Hospital

BMD003 (CFTR mRNA) is one of 41 small molecule programs targeting Cystic Fibrosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisRecruiting

Cystic FibrosisPhase 1

Recruiting

Competition

Competitive Landscape

105 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Ibsrela

AArdelyx

Phase 3

1 2

Avelox

Bayer

Phase 2

1 3

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 4

Sirturo

WWim Janssens

Phase 2

1 5

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

19 6

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 7

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 8

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

4 9

Verapamil Hydrochloride

Mylan Pharmaceuticals Inc

Phase 3

1 10

Hyperpolarized Xenon-129

TThunder Bay Regional Health Research Institute

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Cystic Fibrosis

NCT07485543

Clinical

Trials by Indication[1]

Cystic Fibrosis1 trial

A Prospective, Single-center, Open-label Clinical Study to Evaluate the Safety and Efficacy of Inhaled BMD003(CFTR mRNA) in Chinese Patients Aged 12 Years and Above With Cystic Fibrosis

Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT07485543·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BMD003 (CFTR mRNA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMD003 (CFTR mRNA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMD003 (CFTR mRNA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: PPeking Union Medical College Hospital

BMD003 (CFTR mRNA)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News